[go: up one dir, main page]

DK0811062T3 - Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf - Google Patents

Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf

Info

Publication number
DK0811062T3
DK0811062T3 DK96907061T DK96907061T DK0811062T3 DK 0811062 T3 DK0811062 T3 DK 0811062T3 DK 96907061 T DK96907061 T DK 96907061T DK 96907061 T DK96907061 T DK 96907061T DK 0811062 T3 DK0811062 T3 DK 0811062T3
Authority
DK
Denmark
Prior art keywords
carcinomas
self
applications
production
associated antigens
Prior art date
Application number
DK96907061T
Other languages
English (en)
Inventor
Jeffrey Schlom
Dennis Panicali
Kwong Y Tsang
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0811062T3 publication Critical patent/DK0811062T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96907061T 1995-02-22 1996-02-13 Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf DK0811062T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/396,385 US6001349A (en) 1995-02-22 1995-02-22 Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
PCT/US1996/002156 WO1996026271A1 (en) 1995-02-22 1996-02-13 Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof

Publications (1)

Publication Number Publication Date
DK0811062T3 true DK0811062T3 (da) 2009-10-26

Family

ID=23566990

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96907061T DK0811062T3 (da) 1995-02-22 1996-02-13 Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf

Country Status (10)

Country Link
US (2) US6001349A (da)
EP (1) EP0811062B1 (da)
JP (1) JP4059920B2 (da)
AU (1) AU711899B2 (da)
CA (1) CA2213451C (da)
DE (1) DE69637969D1 (da)
DK (1) DK0811062T3 (da)
ES (1) ES2329427T3 (da)
PT (1) PT811062E (da)
WO (1) WO1996026271A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
JP4475683B2 (ja) * 1996-07-25 2010-06-09 アメリカ合衆国 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO1999008713A1 (en) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
DE69824023T2 (de) * 1997-10-10 2005-05-12 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
EP1447414B1 (en) * 1997-10-10 2007-06-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Antagonist peptides of carcinoembryonic antigen (CEA)
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
DE69941703D1 (de) * 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
AU2001258102B2 (en) 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP1305414A2 (en) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Modified cea and uses thereof
JP2004508340A (ja) * 2000-09-01 2004-03-18 エピミューン　インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
EP1370668B1 (en) * 2001-03-08 2006-02-22 Akzo Nobel N.V. Leporipox-based vector vaccines
ES2675735T3 (es) 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
GB2396814B (en) 2001-11-30 2006-07-19 Isis Innovation Fowlpox vector
AU2003225866A1 (en) * 2002-03-22 2003-10-13 Aventis Pasteur, Inc. Peptide epitopes recognized by antigen specific cd8+ t lymphocytes
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
AU2003273679A1 (en) * 2002-06-11 2003-12-22 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
EP1670926B1 (en) * 2003-10-08 2011-04-20 Sanofi Pasteur Limited Modified cea /b7 vector
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
EP2023954B1 (en) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
EP2444410A3 (en) * 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2424999A1 (en) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modified immunization vectors
WO2012019125A2 (en) 2010-08-06 2012-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
EP3193592A1 (en) 2014-09-19 2017-07-26 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
EP3347051A4 (en) 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
KR102598120B1 (ko) 2016-06-03 2023-11-07 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
ES2059330T3 (es) * 1986-08-13 1994-11-16 Miles Inc Un cdna codificador de antigeno carcinoembrionico.
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
ATE248924T1 (de) * 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5764734A (en) * 1994-12-21 1998-06-09 Motorola, Inc. Method and system for controlling access to a channel

Also Published As

Publication number Publication date
EP0811062B1 (en) 2009-07-15
AU711899B2 (en) 1999-10-21
DE69637969D1 (de) 2009-08-27
PT811062E (pt) 2009-09-28
CA2213451A1 (en) 1996-08-29
US6001349A (en) 1999-12-14
WO1996026271A1 (en) 1996-08-29
AU5024096A (en) 1996-09-11
ES2329427T3 (es) 2009-11-25
JP4059920B2 (ja) 2008-03-12
CA2213451C (en) 2013-11-12
JPH11507804A (ja) 1999-07-13
US6319496B1 (en) 2001-11-20
EP0811062A1 (en) 1997-12-10

Similar Documents

Publication Publication Date Title
DK0811062T3 (da) Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf
NO931138D0 (no) Omco-foetalt gen, genprodukt og anvendelse derav
NO172173C (no) Fremgangsmaate for fremstilling av en artikkel av bundet, partikkelformig materiale og bindemiddel for bruk deri
DK218386D0 (da) Konjugater af antistof og terapeutisk middel
TR26456A (tr) IKIZ-BÖLMELI PAKETLER VE IKIZ-BÖLMELI PAKETLERIN üRETILMESINE MAHSUS YÖNTEMLER VE CIHAZLAR.
DE69009540D1 (de) Arzneimittel enthaltendes Heftpflaster.
DK335389D0 (da) Komposit-agrotekstil og anvendelser af dette
IS3721A7 (is) Viðskeytt benzimidazole, aðferð við lögun þeirra og lyfjafræðileg notkun
GR890100033A (el) Μέ?οδος παρασκευής διδεοξυδιδευδροκαρβοκυκλικών νουκλεοσιδών.
DK0808249T3 (da) Sammensætninger og donorelementer til termisk masseoverføring til anvendelse ved fremstilling af produkter til skiltning
FI841448A0 (fi) Anordning foer upprullning av en materialbana, speciellt en pappersbana, pao en hylsa.
DK171585D0 (da) Fremgangsmaade til fremstilling af rismateriale og produkt, fremstillet derved
IT8719292A0 (it) Composizione di anticorpi monoclonali umani cross-protettivi.
DE68906462D1 (de) Praeparat aus reiskleie und dessen verwendung.
NO960464D0 (no) Redispergerbare, pulverformige kjerne-mantel-polymerer, deres fremstilling og anvendelse
DE3882727D1 (de) Mycoplasma-membran-antigene und ihre verwendung.
DK436184D0 (da) Specifikke cea-familie-antigener, antistoffer specifikke dertil og deres anvendelsesmaader
NO962157L (no) Nye glukose- og soforoselipider, en fremgangsmåte for fremstilling derav og anvendelse av lipidene
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
BR8703763A (pt) Colar de desengate rapido
DK307385D0 (da) Morpholinolforbindelser, deres fremstilling og farmaceutiske anvendelse
DE69024393D1 (de) Hitzebeständige Klebematerialien
NO890061D0 (no) Fremstilling og anvendelse av gallosilikataromatiseringskatalysator.
NO893818D0 (no) Produksjon og anvendelse av hybride, monoklonale antistoffer.
EP0229107A4 (en) PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO -i(PSEUDOMONAS AERUGINOSA) EXOTOXIN A.